Navigation Links
Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
Date:2/4/2016

LONDON, Feb. 4, 2016 /PRNewswire/ -- Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth

Summary

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

Scope

Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
- What factors are driving the market growth?
- How can the factors limiting growth be overcome?
There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
- What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
- How does the composition of the pipeline compare with that of the existing market?
Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
- How will this affect their revenues in this period?
- How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?
The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.
- What is driving this continued market dominance?
- Who will the new market players be?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
- Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals
Download the full report: https://www.reportbuyer.com/product/3596608/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Viral Partnering Deal Trends, Players and Financials Analysis Report 2016
2. Global Breast Pumps Market Assessment & Forecast: 2015 - 2019
3. Global Life Science Microscopy Devices Market Assessment & Forecast: 2015 - 2019
4. Haemophilus influenzae Infections Global Clinical Trials Review, H2, 2015
5. Atomic Spectroscopy Market by Technology & by Application - Analysis & Global Forecast to 2020
6. Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
7. Global Blood Glucose Testing and Diabetes Management Report 2015
8. HeartWare Presentation At The Leerink Partners 5th Annual Global Healthcare Conference To Be Webcast
9. ARMO BioSciences to Present at the Leerink Partners Global Healthcare Conference
10. Medical Ceramics Market by Material, by Application, and by Region - Global Forecast to 2020
11. Luminex Corporation To Present At 2016 Leerink Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... , ... Drs. Nickelice Brand and Chris Williams restore smiles of Ocala, FL ... Dental implants are a nearly permanent, comfortable and efficient way for patients to replace ... rate when placed by highly trained professionals such as Drs. Brand and Williams, providing ...
(Date:9/17/2019)... LUIS OBISPO, Calif. (PRWEB) , ... September 17, 2019 , ... Summer is a time ... of it is good for our teeth and gums. Dr. Douglas Ng, family dentist ... , Warm weather is the time for ice cream, and popsicles and ice-filled cold drinks ...
(Date:9/14/2019)... CITY, Calif. (PRWEB) , ... ... ... World Molecular Imaging Society (WMIS) annual congress in Montreal provided a plethora ... studies highlighted presentations on Artificial Intelligence (AI) to detect breast cancer, response ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... ... Cars has hosted an annual event each fall for years in an effort to help ... for every vehicle purchased from Sept. 17 to Nov. 14, the dealership will donate $50 ... also been referred to as, “50 for 50.” , Though the Hall Cars ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... contributing to the long-term health of canines – specifically golden retrievers - through ... Retrievers will die from cancer – one out of five retrievers in the ...
(Date:9/17/2019)... ... September 17, 2019 , ... What ... the lives of some cancer patients? In companion presentations at the American Society ... Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... Warriors , with the goal of providing resources to assist researchers and encourage ... a progressive disease causing abnormal iron deposits in the brain. , BPAN ...
(Date:9/14/2019)... CITY, Calif. (PRWEB) , ... ... ... Molecular Imaging Society (WMIS) showcased several first-in-human studies on the detection and ... Montreal. Highlighting two examples of these ground-breaking studies were noninvasive detection of ...
Breaking Medicine News(10 mins):